← Lantheus Holdings, Inc. (LNTH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Lantheus Holdings, Inc. (LNTH)
In Vitro & In Vivo Diagnostic Substances · market cap $6.5B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
11
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Lantheus Holdings (LNTH) is a ~$6.9B market-cap radiopharmaceutical and diagnostic imaging company with 808 employees, generating $1.54B in 2025 revenue and $234M net income. Its commercial anchor is DEFINITY (an ultrasound enhancing agent in Phase 3 for cardiac disease), supplemented by a pipeline spanning cardiac PET imaging (Flurpiridaz F18), Alzheimer's diagnostics ([18F]PI-2620, Florbetaben), cardiac amyloidosis, Kawasaki disease, and early-stage oncology. The highest-impact near-term catalyst is the estimated June 2027 Phase 3 readout for [18F]PI-2620 in Alzheimer's disease.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 3 · [18F]PI-2620imp 9/10
- 2027-08-15 (est.)Phase 2 · LNTH2403 Phase 1 doseimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DEFINITY | Phase 3 | Cardiac Disease |
| LNTH2403 Phase 1 dose | Phase 2 | Relapsed / Refractory Osteosarcoma |
| Flurpiridaz F18 | Phase 3 | Coronary Artery Disease |
| DEFINITY® | Phase 3 | Cardiac Disease |
| BMS747158 | Phase 2 | Ischemia |
| Sestamibi | Phase 3 | Kawasaki Disease |
| Technetium Tc99m Sestamibi | Phase 2 | Kawasaki Disease |
| Peflutren Lipid Microsphere Injectable Suspension | Phase 2 | Liver Disease |
| [18F]florbetaben | Phase 3 | Cardiac Amyloidosis |
| [18F]PI-2620 | Phase 3 | Alzheimer Disease |
| Florbetaben (BAY94-9172) | Phase 3 | Alzheimer Disease |
Price & technical context
3-month
-2.9%
6-month
+31.2%
12-month
+93.4%
52-wk range
$50.69–$110.94
vs 50-day MA
-0.9%
vs 200-day MA
+13.4%
Realized vol
33.1%
Max drawdown
-57.1%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LNTH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.